156 related articles for article (PubMed ID: 21476971)
1. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jul; 12(6):549-69. PubMed ID: 21476971
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
Niwa T; Yamazaki H
Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
4. Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
Totah RA; Allen KE; Sheffels P; Whittington D; Kharasch ED
J Pharmacol Exp Ther; 2007 Apr; 321(1):389-99. PubMed ID: 17259447
[TBL] [Abstract][Full Text] [Related]
5. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
[TBL] [Abstract][Full Text] [Related]
6. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.
Li XQ; Weidolf L; Simonsson R; Andersson TB
J Pharmacol Exp Ther; 2005 Nov; 315(2):777-87. PubMed ID: 16093273
[TBL] [Abstract][Full Text] [Related]
7. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
[TBL] [Abstract][Full Text] [Related]
8. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment.
Bu HZ
Curr Drug Metab; 2006 Apr; 7(3):231-49. PubMed ID: 16611019
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms.
Subrahmanyam V; Renwick AB; Walters DG; Price RJ; Tonelli AP; Lake BG
Xenobiotica; 2002 Jun; 32(6):521-34. PubMed ID: 12160484
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes.
Miura M; Satoh S; Tada H; Habuchi T; Suzuki T
Eur J Clin Pharmacol; 2006 Feb; 62(2):113-7. PubMed ID: 16389533
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Liu KH; Kim MJ; Shon JH; Moon YS; Seol SY; Kang W; Cha IJ; Shin JG
Xenobiotica; 2005 Jan; 35(1):27-38. PubMed ID: 15788366
[TBL] [Abstract][Full Text] [Related]
14. The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes.
Chou YC; Chung YT; Liu TY; Wang SY; Chau GY; Chi CW; Soucek P; Krausz KW; Gelboin HV; Lee CH; Ueng YF
J Pharm Sci; 2010 Feb; 99(2):1063-77. PubMed ID: 19593786
[TBL] [Abstract][Full Text] [Related]
15. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
16. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
Desta Z; Soukhova N; Mahal SK; Flockhart DA
Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
[TBL] [Abstract][Full Text] [Related]
17. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
[TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
20. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
